- Home
- HEPS vs CDNA Comparison
HEPS vs CDNA Comparison
Compare HEPS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HEPS
- CDNA
- Stock Information
- Founded
- HEPS 2000
- CDNA 1998
- Country
- HEPS Turkey
- CDNA United States
- Employees
- HEPS N/A
- CDNA N/A
- Industry
- HEPS Catalog/Specialty Distribution
- CDNA Medical Specialities
- Sector
- HEPS Consumer Discretionary
- CDNA Health Care
- Exchange
- HEPS Nasdaq
- CDNA Nasdaq
- Market Cap
- HEPS 883.5M
- CDNA 1.0B
- IPO Year
- HEPS 2021
- CDNA 2014
- Fundamental
- Price
- HEPS $2.88
- CDNA $19.04
- Analyst Decision
- HEPS
- CDNA Buy
- Analyst Count
- HEPS 0
- CDNA 6
- Target Price
- HEPS N/A
- CDNA $30.33
- AVG Volume (30 Days)
- HEPS 367.1K
- CDNA 996.2K
- Earning Date
- HEPS 07-01-2025
- CDNA 07-30-2025
- Dividend Yield
- HEPS N/A
- CDNA N/A
- EPS Growth
- HEPS N/A
- CDNA N/A
- EPS
- HEPS N/A
- CDNA 1.07
- Revenue
- HEPS $1,471,066,066.00
- CDNA $346,421,000.00
- Revenue This Year
- HEPS $23.29
- CDNA $13.31
- Revenue Next Year
- HEPS $25.43
- CDNA $15.46
- P/E Ratio
- HEPS N/A
- CDNA $17.61
- Revenue Growth
- HEPS 42.87
- CDNA 25.92
- 52 Week Low
- HEPS $1.91
- CDNA $13.48
- 52 Week High
- HEPS $4.05
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- HEPS 59.54
- CDNA 55.64
- Support Level
- HEPS $2.69
- CDNA $18.51
- Resistance Level
- HEPS $2.99
- CDNA $19.62
- Average True Range (ATR)
- HEPS 0.10
- CDNA 0.84
- MACD
- HEPS 0.03
- CDNA 0.02
- Stochastic Oscillator
- HEPS 76.60
- CDNA 66.12
About HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.